MX2019008001A - Regimenes de dosificacion y formas de dosificacion para inhibicion dirigida de factor beta de crecimiento transformante. - Google Patents
Regimenes de dosificacion y formas de dosificacion para inhibicion dirigida de factor beta de crecimiento transformante.Info
- Publication number
- MX2019008001A MX2019008001A MX2019008001A MX2019008001A MX2019008001A MX 2019008001 A MX2019008001 A MX 2019008001A MX 2019008001 A MX2019008001 A MX 2019008001A MX 2019008001 A MX2019008001 A MX 2019008001A MX 2019008001 A MX2019008001 A MX 2019008001A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- dosing regimens
- inhibition
- targeted tgf
- independent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endoscopes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443698P | 2017-01-07 | 2017-01-07 | |
| US201762581978P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/012604 WO2018129331A1 (en) | 2017-01-07 | 2018-01-05 | Dosing regimens and dosage forms for targeted tgf-b inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008001A true MX2019008001A (es) | 2019-09-09 |
Family
ID=62791283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008001A MX2019008001A (es) | 2017-01-07 | 2018-01-05 | Regimenes de dosificacion y formas de dosificacion para inhibicion dirigida de factor beta de crecimiento transformante. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190330375A1 (https=) |
| EP (1) | EP3565599A4 (https=) |
| JP (1) | JP2020514290A (https=) |
| KR (1) | KR20190102059A (https=) |
| CN (1) | CN110198738A (https=) |
| AU (1) | AU2018205233A1 (https=) |
| BR (1) | BR112019013924A2 (https=) |
| CA (1) | CA3048646A1 (https=) |
| CL (1) | CL2019001871A1 (https=) |
| IL (1) | IL267856A (https=) |
| MX (1) | MX2019008001A (https=) |
| PH (1) | PH12019501574A1 (https=) |
| RU (1) | RU2019124875A (https=) |
| SG (1) | SG11201906157YA (https=) |
| WO (1) | WO2018129331A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| CN108348578B (zh) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| ES2948647T3 (es) | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas |
| KR20210022680A (ko) * | 2018-06-22 | 2021-03-03 | 메르크 파텐트 게엠베하 | 담도암의 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘 |
| AU2019299318A1 (en) * | 2018-07-02 | 2021-01-21 | Merck Patent Gmbh | Combination therapy with targeted TGF-B inhibition for treatment of advanced non-small cell lung cancer |
| AU2019301070B2 (en) | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| US12559539B2 (en) * | 2018-11-09 | 2026-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | TGF-beta receptor fusion protein pharmaceutical composition and use thereof |
| CN113677711B (zh) | 2019-01-30 | 2025-05-30 | 供石公司 | TGFβ的LTBP复合特异性抑制剂及其用途 |
| BR112021024820A2 (pt) * | 2019-06-10 | 2022-01-25 | Shandong Boan Biotechnology Co Ltd | Proteína de fusão bifuncional contra pdl1 e tgfss e uso da mesma |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| EP4049012A1 (en) * | 2019-10-24 | 2022-08-31 | Amgen Inc. | Systems and approaches for drug delivery |
| WO2021084124A1 (en) * | 2019-11-01 | 2021-05-06 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| WO2021092079A1 (en) | 2019-11-05 | 2021-05-14 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| BR112022010824A2 (pt) * | 2019-12-11 | 2022-08-23 | Wuxi Biologics Ireland Ltd | Anticorpo bifuncional contra pd-l1 e tgf¿ |
| JP7730817B6 (ja) * | 2019-12-20 | 2025-09-26 | アレス トレーディング ソシエテ アノニム | ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物 |
| CN111118064B (zh) * | 2019-12-24 | 2022-10-25 | 华南理工大学 | 一种精子生成障碍动物模型及其制备方法与应用 |
| TW202135862A (zh) | 2020-01-11 | 2021-10-01 | 美商供石公司 | TGFβ抑制劑及其用途 |
| CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| US20230093512A1 (en) * | 2020-02-18 | 2023-03-23 | Nanjing GenScript Biotech Co., Ltd. | Fusion proteins and uses thereof |
| EP4093779A4 (en) * | 2020-02-25 | 2024-03-06 | Wuxi Biologics Ireland Limited | BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| CN116323657B (zh) * | 2020-09-24 | 2023-12-08 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| US20240148903A1 (en) | 2021-03-08 | 2024-05-09 | Nanjing GenScript Biotech Co., Ltd. | Delivery of antibody by using dual viral vector system |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| PE20241477A1 (es) * | 2021-11-19 | 2024-07-17 | Merus Nv | Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785682A (en) * | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20130110045A1 (en) * | 2011-10-31 | 2013-05-02 | Ming-Yuan Wu | Single use intravenous therapy administering device with needle safety covers |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| ES2822665T3 (es) * | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| BR112016014952A2 (pt) * | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| US10828353B2 (en) * | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| EP3770171A1 (en) * | 2015-04-03 | 2021-01-27 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| ES2835866T5 (es) * | 2015-05-12 | 2024-12-02 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
-
2018
- 2018-01-05 WO PCT/US2018/012604 patent/WO2018129331A1/en not_active Ceased
- 2018-01-05 RU RU2019124875A patent/RU2019124875A/ru unknown
- 2018-01-05 AU AU2018205233A patent/AU2018205233A1/en not_active Abandoned
- 2018-01-05 SG SG11201906157YA patent/SG11201906157YA/en unknown
- 2018-01-05 CA CA3048646A patent/CA3048646A1/en active Pending
- 2018-01-05 KR KR1020197022795A patent/KR20190102059A/ko not_active Ceased
- 2018-01-05 JP JP2019536228A patent/JP2020514290A/ja active Pending
- 2018-01-05 EP EP18736497.1A patent/EP3565599A4/en active Pending
- 2018-01-05 BR BR112019013924-9A patent/BR112019013924A2/pt not_active Application Discontinuation
- 2018-01-05 MX MX2019008001A patent/MX2019008001A/es unknown
- 2018-01-05 CN CN201880006085.0A patent/CN110198738A/zh active Pending
-
2019
- 2019-07-02 US US16/460,792 patent/US20190330375A1/en not_active Abandoned
- 2019-07-03 PH PH12019501574A patent/PH12019501574A1/en unknown
- 2019-07-04 IL IL267856A patent/IL267856A/en unknown
- 2019-07-05 CL CL2019001871A patent/CL2019001871A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019013924A2 (pt) | 2020-02-11 |
| CL2019001871A1 (es) | 2019-12-13 |
| JP2020514290A (ja) | 2020-05-21 |
| CN110198738A (zh) | 2019-09-03 |
| WO2018129331A1 (en) | 2018-07-12 |
| KR20190102059A (ko) | 2019-09-02 |
| SG11201906157YA (en) | 2019-08-27 |
| PH12019501574A1 (en) | 2019-11-04 |
| IL267856A (en) | 2019-09-26 |
| RU2019124875A (ru) | 2021-02-08 |
| CA3048646A1 (en) | 2018-07-12 |
| EP3565599A1 (en) | 2019-11-13 |
| EP3565599A4 (en) | 2020-07-01 |
| US20190330375A1 (en) | 2019-10-31 |
| RU2019124875A3 (https=) | 2021-07-08 |
| AU2018205233A1 (en) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008001A (es) | Regimenes de dosificacion y formas de dosificacion para inhibicion dirigida de factor beta de crecimiento transformante. | |
| PH12022550886A1 (en) | INHIBITING HUMAN INTEGRIN a4Ã7 | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| MX2016015346A (es) | Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| GEAP202415222A (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| MX2023014093A (es) | Compuestos que interactuan con glicano y metodos de uso. | |
| MX372883B (es) | Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer. | |
| PH12019501763A1 (en) | Method of reducing neutropenia | |
| PH12016500413A1 (en) | Cyclic peptidomimetic compounds as immunomodulators | |
| MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
| MX2021005236A (es) | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. | |
| EP2866795A4 (en) | POLYENOLZIN BINDER FOR THE ACTIVE PROMOTION OF THE INACTIVATION OF CANCER STRAIN CELLS AND FOR THE POTENTIATING OF CYTOTOXIC ANTITUMOROUS SUBSTANCES | |
| MX2019013862A (es) | Terapia de combinacion. | |
| PE20200602A1 (es) | Compuesto macrociclico y sus usos | |
| MX2019009630A (es) | Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion. | |
| EA201791049A1 (ru) | Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы) | |
| MY205197A (en) | Methyllactam ring compound and pharmaceutical use thereof | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| MX2017015418A (es) | Composiciones y metodos de uso de beta-hidroxi-beta-metilbutirato (hmb) para reducir grasa corporal. | |
| MX373272B (es) | Terapia de combinacion. | |
| MX2017001176A (es) | Terapia de combinacion. | |
| MX2012012915A (es) | Adherencia de inmunogeno y metodo para formar y utilizar el mismo. | |
| MX2020011638A (es) | Regimenes de dosificacion para una inhibicion dirigida del factor de crecimiento transformante beta (tgf-beta) en el tratamiento del cancer en sujetos no tratados previamente. | |
| PH12016502042A1 (en) | Drug delivery conjugates for treating resistant cancer and for use in combination therapy | |
| MX2019010086A (es) | Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1. |